MET Amplification
Showing 1 - 25 of 1,958
NSCLC Trial (HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin)
Not yet recruiting
- Non-Small Cell Lung Cancer
- HS-10241+ Almonertinib
- Pemetrexed + Cisplatin /Carboplatin
- (no location specified)
Oct 29, 2023
Non-squamous Non-small-cell Lung Cancer, Stage IV NSCLC, ROS1 Gene Rearrangement Trial in Toronto (Crizotinib)
Recruiting
- Non-squamous Non-small-cell Lung Cancer
- +4 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Jan 8, 2023
Advanced Gastric Adenocarcinoma Trial in Seoul (Volitinib)
Completed
- Advanced Gastric Adenocarcinoma
-
Seoul, Korea, Republic ofSamsung Medical center
Jun 13, 2022
Lung Non-Small Cell Carcinoma Trial (Amivantamab, Biospecimen Collection, Computed Tomography)
Not yet recruiting
- Lung Non-Small Cell Carcinoma
- Amivantamab
- +3 more
- (no location specified)
Oct 30, 2023
NSCLC Trial in Shanghai (Savolitinib + Osimertinib, Pemetrexed + Cisplatin /Carboplatin)
Recruiting
- Non-small Cell Lung Cancer
- Savolitinib + Osimertinib
- Pemetrexed + Cisplatin /Carboplatin
-
Shanghai, Shanghai, ChinaShanghai Chest Hospital
Nov 29, 2021
NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)
Recruiting
- Non-Small Cell Lung Cancer
- +5 more
- Toripalimab
- +3 more
-
Guanzhou, Guangdong, ChinaGuangdong Lung Cancer Institute, Guangdong Provincial People's H
Apr 4, 2023
NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)
Terminated
- Carcinoma, Non-Small-Cell Lung
- capmatinib
- +4 more
-
Kashiwa, Chiba, Japan
- +3 more
Jan 31, 2023
Non Small Cell Lung Cancer (NSCLC), Metastases to the Brain Trial in Pittsburgh (cabozantinib)
Terminated
- Non Small Cell Lung Cancer (NSCLC)
- Metastases to the Brain
-
Pittsburgh, PennsylvaniaUniversity of Pittsburgh Cancer Institute- Hillman Cancer Center
Mar 8, 2021
Advanced (Stage IIIB/IV) NSCLC (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification Trial in Worldwide
Active, not recruiting
- Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification
-
Duarte, California
- +140 more
Jun 7, 2022
Negative T790M Mutation and Met Amplification Trial in Beijing (Glumetinib)
Unknown status
- Negative T790M Mutation and Met Amplification
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Apr 7, 2020
Stomach Cancer, Adenocarcinoma Trial in Seoul (Durvalumab, Savolitinib)
Recruiting
- Stomach Cancer, Adenocarcinoma
-
Seoul, Korea, Republic ofSamsung Medical Center
Jan 10, 2023
NSCLC Trial in Pittsburgh (Capmatinib)
Not yet recruiting
- Non-small Cell Lung Cancer
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Jan 9, 2023
Colorectal Tumors Trial in Worldwide (Tepotinib, Cetuximab)
Active, not recruiting
- Colorectal Neoplasms
- Tepotinib
- Cetuximab
-
Phoenix, Arizona
- +66 more
Nov 19, 2021
Brain Tumor Trial in Houston (tepotinib, tepotinib plus osimertinib)
Not yet recruiting
- Brain Tumor
- tepotinib
- tepotinib plus osimertinib
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2022
NSCLC Trial in Worldwide (Tepotinib, Osimertinib)
Active, not recruiting
- Non-small Cell Lung Cancer
-
Yuma, Arizona
- +178 more
Dec 19, 2022
Oesophageal Adenocarcinoma, Gastric Adenocarcinoma Trial in France (Capmatinib, Spartalizumab)
Suspended
- Oesophageal Adenocarcinoma
- Gastric Adenocarcinoma
-
Besançon, France
- +6 more
Feb 1, 2023
c-MET Expression and EGFR Gene Mutation Correlation With
Completed
- Non-small Cell Lung Cancer Metastatic
- Non-small Cell Lung Cancer Recurrent
-
Hwasun, Korea, Republic ofChonnam National University Hwasun Hospital
Aug 1, 2021
Hematologic Cancers, Solid Tumors, Metastatic Cancer Trial in Villejuif (Crizotinib)
Active, not recruiting
- Hematologic Cancers
- +2 more
-
Villejuif, Ile De France, FranceGustave Roussy
Sep 5, 2022
Head and Neck Squamous Cell Carcinoma Trial in Toronto (MET-4)
Active, not recruiting
- Head and Neck Squamous Cell Carcinoma
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Jan 8, 2023
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (procedure, drug, biological)
Not yet recruiting
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
- Biospecimen Collection
- +5 more
- (no location specified)
Nov 30, 2022
NSCLC Trial in Worldwide (Capmatinib, Amivantamab)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
-
Orange, California
- +40 more
Aug 3, 2022